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Abstract Recently, we have shown that inhibition of caspase-3-
like caspases is the most effective treatment strategy to protect
adult rat retinal ganglion cells from secondary death following
optic nerve transection. In the present study, we localized active
caspase-3 in axotomized retinal ganglion cells in vivo and
demonstrated a co-localization of the active p20 fragment and
TUNEL-staining in some of these cells. In line with this, we
detected an enhanced cleavage and activity of caspase-3 protein
in retinal tissue after lesion, while caspase-3 mRNA expression
remained unchanged. These data suggest caspase-3 as an
important mediator of secondary retinal ganglion cell death
following axotomy in vivo.
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1. Introduction
Following optic nerve (ON) transection, the vast majority
of retinal ganglion cells (RGCs) dies by apoptosis [1,2], with a
maximum of cell death occurring between days 5 and 7 post-
lesion [3]. Various potential neuroprotective agents such as
brain-derived neurotrophic factor, NT-4 and glial cell line-
derived neurotrophic factor have already been successfully
tested in this experimental paradigm [4^7]. However, none
of them was able to rescue more than 50^60% of RGCs at
day 14 after ON transection. In recent years, a family of
cysteine proteases, named caspases [8], has been characterized.
It could be demonstrated in vitro and in vivo that these pro-
teases are important mediators of apoptotic cell death during
development and in disease states [9^12]. Recently, we have
shown that inhibition of caspases rescues axotomized RGCs
from secondary neuronal death in vivo, with speci¢c inhibi-
tion of caspase-3-like caspases being the most e¡ective [13].
We therefore hypothesized that caspase-3 is the major medi-
ator of RGC death after ON transection. In the present study,
we investigated retinal caspase-3 activation in more detail em-
ploying reverse transcription (RT-) PCR, Western blot anal-
ysis, caspase activity assays and immunohistochemistry.
2. Material and methods
2.1. Surgery and drug administration
Adult Sprague-Dawley rats (200^250 g, Charles River Wiga, Sulz-
feld, Germany) were used in this study. Transection of the ON ap-
proximately 2 mm from the posterior eye pole without damaging the
retinal blood supply was performed as described before [13]. In a
subset of animals, the speci¢c and irreversible inhibitor of caspase-
3-like caspases benzyloxycarbonyl-Asp-Glu-Val-Asp-chloromethylke-
tone (z-DEVD-cmk: Bachem, Germany) dissolved in 2% dimethyl-
sulfoxide (DMSO, Sigma/Germany) was injected intravitreously at a
concentration of 4000 ng and a volume of 2 Wl on days 0 and 4
following ON transection by means of a small glass electrode accord-
ing to a protocol described in more detail elsewhere [13].
2.2. Caspase-3 £uorogenic activity assay
Animals received an overdose of chloral hydrate and the eyes were
removed either 6 h, 2 days, 3 days post-lesion or on day 4 post-lesion
approximately 6 h following the second caspase inhibitor injection
(see above). Untreated contralateral retinae served as controls. Reti-
nae were homogenized, lysed (150 mM NaCl, 50 mM Tris pH 8.0,
2 mM EDTA, 1% Triton, containing 0.1 mM PMSF, and 2 Wg/ml
pepstatin, leupeptin and aprotinin) for 10 min at 37‡C and cell debris
pelleted at 14 000Ug for 15 min. The protein concentration of the
supernatant was determined using the BCA reagent (Pierce, Rockford,
IL, USA). The caspase-3 £uorogenic activity assay was performed
with 30 Wl of fresh protein lysates (control (n = 9), axotomy day 4
(n = 6), axotomy day 4 treated with z-DEVD-cmk on days 0 and
4 (n = 4)) which were incubated with 100 WM Ac-Asp-Glu-Val-Asp-
AMC (DEVD-AMC), a £uorogenic substrate of caspase-3. Fluores-
cence was determined as optical density (OD) units, every 15 min for
2 h using 360 nm excitation and 460 nm emission wavelengths (Cyto-
Flour 2350) and calculated as the increase in OD per Wg protein over
time. Statistics were performed applying one-way ANOVA followed
by a Duncan test.
2.3. Western blot analysis for active caspase-3
Proteins of axotomized day 4 retinal tissue and contralateral con-
trols processed as described above were separated on SDS-PAGE
(50 Wg 12% versus 20 Wg 15%), transferred to a nitrocellulose or
PVDF membrane and blocked with 5% skim milk in PBS-T (0.1%
Tween 20). Proteins were detected by incubating with rabbit anti-
caspase-3 (1:1500 CM-1 [14], 3 h at room temperature (RT)) followed
by goat anti-rabbit HRP (1:2000, 1 h at RT), washing for three times
in PBS-T and applying the ECL-Plus reagent (Amersham, Arlington
Heights, IL, USA) following the supplier’s instructions.
2.4. RT-PCR for caspase-3
For RT-PCR experiments, after dissection, retinae were immedi-
ately snap-frozen in liquid nitrogen. Total RNA was extracted using
Trizol reagent (Gibco Life Technologies GmbH, Germany) following
the manufacturer’s protocol. RT-PCR was performed according to
standard protocols. For cDNA synthesis, 2.5 Wg total RNA was re-
verse-transcribed with Superscript II (Gibco BRL) in a volume of
50 Wl, applying the manufacturer’s instructions. The reaction was
primed using random primers (300 ng). For a subsequent PCR reac-
tion, 100 ng of ethanol-precipitated cDNA was used as template. The
primer sequences and cycling conditions for semi-quantitative PCR
were the following: 94‡C for 3 min, annealing for 30 s and extension
for 30 s at 72‡C. Caspase-3 primer, forward: TACCCTGA-
AATGGGCTTGTGT, reverse: GTTAACACGAGTGAGGATGTG,
annealing temperature 50‡C, 28 cycles, and G3PDH primer, forward:
GTGATGCTGGTGCTGA, reverse: GCTAAGCAGTTGGTGG,
annealing temperature 50‡C, 23 cycles.
2.5. Active caspase-3 immunohistochemistry and TUNEL
co-localization
Immunolabelling was performed on 4% PFA-¢xed, 16 Wm cryostat
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sections of control retinae and retinae from day 6 post-lesion [7].
Sections were pre-incubated (10% NGS+0.3% Triton in PBS: 1 h
RT), followed by CM-1 antibody [14,15] (1:250^1:1000, 4‡C over-
night) and anti-rabbit IgG-Cy3 (1:125: 1 h RT). Omission of the ¢rst
antibody served as negative control in any immunohistochemical pro-
cedure. Double-labelling of TUNEL/caspase-3 was performed accord-
ing to a protocol published elsewhere [15] with a modi¢ed TUNEL
procedure [3]. Labelling was visualized by £uorescence and confocal
microscopy.
All experiments were con¢rmed at least three times with tissue from
di¡erent animals.
3. Results
To study axotomy-induced changes of caspase-3 mRNA
expression, we used total retinal tissue for RT-PCR at 6, 12
and 24 h, as well as on days 3 and 6 following ON trans-
ection. As indicated in Fig. 1a, caspase-3 mRNA remained
unchanged at all time-points investigated suggesting that casp-
ase-3 might only be regulated on translational or post-trans-
lational levels in lesioned retinal tissue.
Measurement of the caspase-3 activity indeed revealed that
ON transection results in a nearly 2-fold increase in cleavage
of the £uorogenic caspase-3 substrate DEVD-AMC on day 4
post-lesion, which was statistically signi¢cant (P6 0.04) when
compared to controls (Fig. 2). Compared to all other inves-
tigated time-points (data not shown), the di¡erences were
most pronounced on day 4 post-lesion indicating that cas-
pase-3 gets activated until day 4 following ON transection.
In addition, we were able to show that caspase-3 activity
can be e¡ectively reduced to 72% of controls by injecting
the speci¢c and irreversible inhibitor of caspase-3-like casp-
ases into the vitreous body of the lesioned eye (Fig. 2,
P = 0.0525).
To examine whether the increased caspase-3 activity is due
to an increased cleavage of the 32 kDa proform of caspase-3
protein into the active fragments, we performed Western blot
analysis applying the CM-1 antibody which has a preference
for the active p20 fragment of caspase-3. In good agreement
with our results from the activity assay, we detected increased
levels of active caspase-3 in retinal tissue on day 4 following
ON transection when compared to unlesioned contralateral
controls (Fig. 1b). Interestingly, Western blot analysis con-
¢rmed a basal caspase-3 activity in control retinae.
Employing the CM-1 antibody for immunohistochemistry,
we could localize the increased caspase-3 activity in axotom-
ized RGCs on day 4 (data not shown) and day 6 post-lesion
(Fig. 3). RGCs displaying strong £uorescence after axotomy
as presented in Fig. 3b were never detected in control tissue
(Fig. 3a). In contrast, we observed active caspase-3 in the
photoreceptor cell layer of both control and axotomized ret-
inae (Fig. 3). Double-labelling with TUNEL-staining revealed
that on post-lesional day 6, some RGCs were positive for
active caspase-3 and TUNEL simultaneously whereas others
were only reactive for either one (Fig. 3c and d). By using
confocal microscopy (Fig. 4), we observed an exclusively cy-
tosolic localization of active caspase-3 whereas TUNEL-stain-
ing was most pronounced in the nucleus.
4. Discussion
In the present study, we provide evidence that caspase-3
activation following ON transection in vivo is located in axo-
tomized RGCs which are supposed to die shortly thereafter.
First, we examined whether ON lesion regulates retinal casp-
ase-3 mRNA expression. Since we failed to detect such a
regulation, we hypothesize that ON transection results in a
translational or post-translational regulation of caspase-3 ac-
tivity in axotomized RGCs. This is in contrast to results ob-
tained after traumatic brain injury in vivo, where marked
changes in caspase-3 mRNA expression occur in the entire
a¡ected region resulting in a rapid and simultaneous activa-
tion of caspases and subsequent neuronal death within hours
[16]. The lack of mRNA regulation in our lesion paradigm
may be explained by the fact that RGC death following ax-
otomy occurs over an extended period of 3^4 days [3] and is
Fig. 1. Time-course of caspase-3 mRNA expression following ON
transection and Western blot analysis for active caspase-3. (a) Reti-
nal caspase-3 mRNA expression at 6, 12 and 24 h as well as 3 and
6 days after axotomy (A) compared to control retinae (C). At none
of the investigated time-points, any changes in caspase-3 mRNA
levels were detectable. Below, corresponding expression of G3PDH
mRNA as housekeeping gene. (b) Western blot for caspase-3 apply-
ing the CM-1 antibody with a preference for the active p20 frag-
ment. Whereas the amount of the 32 kDa zymogen proform slightly
decreased after axotomy (axo), there is an upregulation of the active
20 kDa fragment of caspase-3. Note that there is a constitutional
p20 expression in unlesioned control retinae (ctrl).
Fig. 2. Retinal activity of caspase-3 following ON transection and
z-DEVD treatment. Data are given as mean OD units þ S.E.M. per
min and Wg protein as a measurement of DEVD-AMC cleavage by
active caspase-3. Compared to control retinae, the activity of cas-
pase-3 on day 4 following ON transection is signi¢cantly increased.
Intraocular injection of 4000 ng z-DEVD-cmk on days 0 and 4
post-lesion results in a massive reduction of caspase-3 activity sup-
porting the neuroprotective e¡ect of z-DEVD as a speci¢c inhibition
of caspase-3 in axotomized RGCs. *, statistically signi¢cant when
compared to control (P6 0.04).
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executed only in a limited subset of axotomized RGCs at the
same time. Another explanation might be that the RGC pop-
ulation represents only about 0.57% of the entire retinal tissue
[17]. Thus, modest changes in caspase-3 mRNA expression in
single cells might escape detection by RT-PCR of total retinal
tissue.
Secondly, we investigated the activity of caspase-3 protein
by speci¢c substrate cleavage in retinal tissue from controls
and after axotomy. In line with our neuroprotection study
which suggested that caspase activation after axotomy is a
rather early event occurring between days 0 and 4 post-lesion
[13], we detected a signi¢cantly increased activity of caspase-3
Fig. 3. Immunohistochemistry for active caspase-3 and double-labelling for TUNEL. Immunolabelling was performed applying the CM-1 anti-
body which recognizes processed caspase-3 (p20 fragment) preferentially to unprocessed zymogen. For double-labelling experiments, immunohis-
tochemistry for active caspase-3 was followed by TUNEL-staining. (a) Micrograph of a control section. Note the lack of immuno-positive cells
in the ganglion cell layer (gcl). An arrowhead points to a cell in the outer nuclear layer (onl) positive for active caspase-3. inl: inner nuclear
layer. Scale bar: 50 Wm. (b) Micrograph of a section 6 days following ON transection stained with the CM-1 antibody. Note the strong £uores-
cence in single RGCs (arrows) which could never be observed in controls indicating an activation of caspase-3 in axotomized RGCs. Immuno-
positive cells in the onl as observed in controls are marked with arrowheads. (c) Micrograph of a section 6 days following ON transection dou-
ble-labelled for active caspase-3 and TUNEL. Arrows point to a cell in the gcl positive for active caspase-3. Below the identical gcl is shown
stained for TUNEL at the same magni¢cation. Note that the cell stained for active caspase-3 is TUNEL-positive as well (arrow). (d) Represen-
tative micrograph 6 days following ON transection double-labelled for active caspase-3 and TUNEL (below). Arrows point to RGCs positive
for either active caspase-3 or TUNEL without double-staining.
Fig. 4. Confocal microscopy of an axotomized RGC, double-stained for active caspase-3 and TUNEL. (a) Immunolabelling for active caspase-
3. Note that the staining is located in the cytoplasm, completely sparing the nucleus. (b) TUNEL-staining of the cell shown in a. Note that the
staining is mainly but not exclusively present in the nucleus, indicating that the cell represents an advanced stage of cell death where the nu-
clear membrane is already damaged. (c) Superimposition of b and c. Scale bar: 5 Wm.
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on day 4 post-lesion. Treatment with an intraocularly injected
inhibitor resulted in a marked decrease in caspase-3 activity
suggesting that the neuroprotective action of z-DEVD-cmk
[13] is based on speci¢c caspase inhibition.
Next, we performed Western blot analysis employing the
CM-1 antibody [14,15] that preferentially detects the active
p20 fragment of caspase-3. In line with observations from
ischemia studies in vivo [15] and con¢rming our results of
the activity assay, we observed an increased level of the active
p20 fragment of caspase-3 on day 4 after axotomy. This sup-
ports our hypothesis that caspase-3 is regulated on the post-
translational level following ON transection. The baseline lev-
els of active caspase-3 in control retinae are in good agree-
ment with our observations from a⁄nity labelling experiments
[13]. Moreover, by immunohistochemistry, we found few pho-
toreceptor cells reactive for active caspase-3 in the outer nu-
clear layer of control and axotomized retinae as well as la-
belled photoreceptor inner segments appearing to be above
background (Fig. 3), which could account for the basal casp-
ase activity in controls. Recent studies support this observa-
tion showing that light exposure especially in albino rats re-
sults in the damage of photoreceptor cells [18,19] involving
apoptotic processes [20]. Since the complete number of casp-
ase-3 substrates has not yet been identi¢ed, caspase-3 could
alternatively play a physiological role in cell metabolism.
Finally, we studied the cellular localization of caspase-3
activation employing the CM-1 antibody for immunohisto-
chemistry. As expected, caspase-3 activation following ON
transection occurred selectively in RGCs which are the only
cell type directly a¡ected by the lesion. As indicated by an
increased caspase-3 activity on day 4 post-lesion, we detected
immuno-positive cells at this time-point as well as on day 6
following axotomy. Since it is known that the number of
TUNEL-positive RGCs reaches its maximum between days
5 and 7 following axotomy [3], we hypothesized that casp-
ase-3 activation precedes TUNEL-staining in the same cell.
To test this, we performed double-labelling experiments on
post-lesional day 6 in which we found a co-localization of
TUNEL-staining/caspase-3 reactivity in a few cells whereas
others were only stained for one or the other. Confocal mi-
croscopy revealed the expected cytosolic localization of active
caspase-3 that has been described after ischemia as well [15].
In contrast, TUNEL-staining displayed a typical nuclear dis-
tribution [3] with a weak £uorescent signal in the cytosol
suggesting a damaged nuclear membrane which one would
expect in advanced stages of apoptosis.
Taken together, these data indicate that secondary death of
the RGC population following ON transection is not a
synchronized event that occurs simultaneously in all cells,
but rather a process lasting several days. Thus, at an advanced
stage of cell death, single cells shortly show activation of
caspase-3 followed by a time-window in which caspase-3
and TUNEL-staining overlap until caspase-3 labelling dimin-
ishes and the cell dies apoptotically. Thus, caspase-3 is sug-
gested as one of the ¢nal and major executioners of RGC
death following axotomy in vivo.
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